Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This Single-Arm Post-Marketing Evaluation will gauge the improvement in function and pain for lumbar spinal stenosis and spondylolisthesis patients with the TOPS System.
This study is being conducted to evaluate the TOPSâ„¢ SP System from ("TOPSâ„¢ System" or "TOPS"). TOPS is an alternative to spinal fusion and is designed to stabilize but not fuse the affected vertebral level to alleviate pain stemming from degenerative spondylolisthesis (abnormal/excessive movement of the vertebrae causing pain in the lower back and legs) and spinal stenosis (narrowing of the spinal canal resulting in compression of nerves producing symptoms of pain, numbness and tingling in the legs).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TOPS System | Other | Post Marketing Study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TOPS System | Device | Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Improvement in ODI and Improvement in VAS leg score v | Composite endpoint - Subjects who exhibit a reduction of 15 percent in their Oswestry Disability Index (ODI) score compared to their preoperative ODI score AND a reduction of at least 20mm (20% improvement) in either of their VAS Leg Score will be considered a success. | 24 months post implantation |
| Measure | Description | Time Frame |
|---|---|---|
| Improvement in back and leg visual analog scales (VAS) | A failure to meet of any of the secondary endpoints will not be considered a therapeutic failure unless such a failure requires subsequent surgical intervention. | 24 month postoperatively |
| Improvement in ZCQ scores |
Not provided
IInclusion Criteria - Prospective subjects must meet all of the following criteria to be considered eligible for inclusion in this clinic study:
Exclusion Criteria - Prospective subjects must not meet any of the exclusion criteria to participate in this clinical study:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Masood Shafafy, MD | Contact | +44 (0)115 9249924 | 61024 | massod.shafafy@nuh.nhs.uk |
| Name | Affiliation | Role |
|---|---|---|
| Masood Shafafy, MD | Queens Medical Centre Nottingham | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Queens Medical Centre | Recruiting | Nottingham | Nottinghamshire | NG7 2UH | United Kingdom |
Not provided
| ID | Term |
|---|---|
| D013130 | Spinal Stenosis |
| D013168 | Spondylolisthesis |
| ID | Term |
|---|---|
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D013169 | Spondylolysis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A failure to meet of any of the secondary endpoints will not be considered a therapeutic failure unless such a failure requires subsequent surgical intervention. |
| 24 months postoperatively |
| Quality of life (SF-36) | A failure to meet of any of the secondary endpoints will not be considered a therapeutic failure unless such a failure requires subsequent surgical intervention. | 24 months postoperatively |
| Maintenance or improvement in neurological symptoms | A failure to meet of any of the secondary endpoints will not be considered a therapeutic failure unless such a failure requires subsequent surgical intervention. | 24 months postoperatively |
| D055009 |
| Spondylosis |